Oral pharmaceutical preparations containing ibuprofen

By synthesizing magnesium oxide in ibuprofen drug preparation, controlling its weight ratio to ibuprofen, and drying it, the problem of difficulty in reducing the taste of ibuprofen solid preparation is solved, and a significant reduction in taste and solid preparation is achieved stability.

CN113038933BActive Publication Date: 2024-11-12SS PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980075319.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-11-16
Filing Date
2019-11-15
Publication Date
2024-11-12
Estimated Expiration
2039-11-15

AI Technical Summary

Technical Problem

When ibuprofen is a solid preparation, its unpleasant taste cannot be reduced sufficiently, and the taste of liquid preparations still needs to be further reduced.

Method used

The weight ratio of ibuprofen or its salt to magnesium oxide is controlled between 0.2 and 1.5, and is incorporated into a pharmaceutical preparation by synthesis to reduce the taste of ibuprofen and during the preparation process. Dry the medium to further improve the taste.

Benefits of technology

It effectively reduces the taste of ibuprofen, especially in solid preparations, avoids darkening and improves the taste and commercial value of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003066397270000121
    Figure BDA0003066397270000121
  • Figure BDA0003066397270000131
    Figure BDA0003066397270000131
  • Figure BDA0003066397270000141
    Figure BDA0003066397270000141
Patent Text Reader

Abstract

Provided is a technology for reducing the unpleasant taste of ibuprofen in an oral pharmaceutical preparation containing ibuprofen. The oral pharmaceutical preparation in which the unpleasant taste of ibuprofen has been reduced comprises (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide, wherein the weight ratio of component (A) to component (B) [(B) / (A)] is 0.2 to 1.5.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to oral pharmaceutical preparations containing ibuprofen, methods for producing said oral pharmaceutical preparations, methods for reducing the unpleasant taste of ibuprofen, etc. Background Technology

[0002] Nonsteroidal antipyretics, analgesics, and anti-inflammatory agents are used to relieve fever and pain; among them, drugs containing ibuprofen (chemical name: 2-(4-isobutylphenyl)propionic acid) are widely prescribed and commercially available. However, although ibuprofen has excellent anti-inflammatory and analgesic effects, its drawback is its unpleasant taste: when ingested orally, it is bitter and irritates the mucous membranes. Therefore, a technique has been proposed to incorporate magnesium chloride to reduce the unpleasant taste of ibuprofen-containing liquid reagents (Patent Document 1).

[0003] Citation List

[0004] Patent documents

[0005] PTL 1: Japanese Unexamined Patent Application Publication No. 2001-31562 Summary of the Invention

[0006] Technical issues

[0007] However, while magnesium chloride can reduce the unpleasant taste to some extent when ibuprofen is in liquid form, it is insufficient when ibuprofen is in solid form. Furthermore, there is a desire to further reduce the unpleasant taste of ibuprofen-containing liquid formulations.

[0008] The problem addressed by this invention is to provide a technique for reducing the unpleasant taste of ibuprofen in oral pharmaceutical formulations containing ibuprofen.

[0009] Solution to the problem

[0010] As a result of efforts to solve the above-mentioned problems, the inventors improved the present invention by the following discovery: by incorporating ibuprofen or its salts or solvates thereof and magnesium oxide into an oral pharmaceutical preparation such that the weight ratio of ibuprofen or its salts or solvates thereof (A) to magnesium oxide (B) [(B) / (A)] is 0.2 to 1.5, the unpleasant taste of ibuprofen can be reduced.

[0011] In particular, the present invention provides the following <1> to <17> .

[0012] <1> An oral pharmaceutical preparation in which the unpleasant taste of ibuprofen has been reduced comprises: (A) ibuprofen or a salt thereof or a solvate thereof, and (B) magnesium oxide, wherein the weight ratio of component (A) to component (B) [(B) / (A)] is 0.2 to 1.5.

[0013] <2> . <1> The oral pharmaceutical preparation described herein, wherein the weight ratio [(B) / (A)] is 0.25 to 1.5.

[0014] <3> . <1> or <2> The oral pharmaceutical preparation described herein, wherein the weight ratio [(B) / (A)] is 0.3 to 1.5.

[0015] <4> . <1> to <3> The oral pharmaceutical preparation described in any one of the following statements, wherein the weight ratio [(B) / (A)] is 0.4 to 1.5.

[0016] <5> . <1> to <4> The oral pharmaceutical preparation described in any one of the following examples is a liquid preparation.

[0017] <6> . <1> to <4> The oral pharmaceutical preparation described in any one of the following examples is a solid dosage form or a semi-solid dosage form.

[0018] <7> . <6> The oral pharmaceutical preparations described herein include dosage forms such as granules, fine granules, powders, uncoated tablets, OD tablets, chewable tablets, gum, jelly, or gummy.

[0019] <8> . <1> to <7> The oral pharmaceutical preparation of any one of the following, wherein the content of component (A) is such that each dose can administer 60 to 800 mg of ibuprofen in free form.

[0020] <9> Used to generate <1> to <8> The method of any one of the oral pharmaceutical preparations includes incorporating (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide into the same composition such that the weight ratio of component (A) to component (B) in the oral pharmaceutical preparation [(B) / (A)] is 0.2 to 1.5.

[0021] <10> . <9> The method described herein further includes a step of drying the composition obtained in the above steps.

[0022] <11> Used to generate <5> The method for oral liquid formulations described herein includes:

[0023] (Step A-1) Incorporating (A) ibuprofen or its salts or solvates thereof and (B) magnesium oxide into the same composition such that the weight ratio of component (A) to component (B) [(B) / (A)] in the liquid oral formulation is 0.2 to 1.5.

[0024] (Step A-2) The step of mixing the composition obtained in step A-1 with water, and

[0025] (Step A-3) The step of heating the liquid composition obtained in step A-2.

[0026] <12> Used to generate <5> The method for oral liquid formulations described herein includes:

[0027] (Step B-1) Incorporating (A) ibuprofen or its salts or solvates thereof and (B) magnesium oxide into the same composition such that the weight ratio of component (A) to component (B) [(B) / (A)] in the liquid oral formulation is 0.2 to 1.5.

[0028] (Step B-2) The step of drying the composition obtained in step B-1.

[0029] (Step B-3) The step of mixing the dried substance obtained in step B-2 with water, and

[0030] (Step B-4) The step of heating the liquid composition obtained in step B-3.

[0031] <13> Used to generate <6> The method for producing a solid or semi-solid oral formulation as described herein includes:

[0032] (Step C-1) Incorporating (A) ibuprofen or its salts or solvates thereof and (B) magnesium oxide into the same composition such that the weight ratio of component (A) to component (B) [(B) / (A)] in the solid or semi-solid oral formulation is 0.2 to 1.5, and

[0033] (Step C-2) The step of drying the composition obtained in step C-1.

[0034] <14> A method for reducing the unpleasant taste of ibuprofen in an oral pharmaceutical preparation comprising ibuprofen or a salt thereof or a solvate thereof, comprising incorporating (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide into the same composition such that the weight ratio of component (A) to component (B) in the oral pharmaceutical preparation [(B) / (A)] is 0.2 to 1.5.

[0035] <15> . <14> The method described herein further includes a step of drying the composition obtained in the above steps.

[0036] <16> A method for suppressing the blackening of an oral pharmaceutical preparation in the production of an oral pharmaceutical preparation comprising (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide; the method comprising incorporating components (A) and (B) into the same composition such that the weight ratio of component (A) to component (B) in the oral pharmaceutical preparation [(B) / (A)] is 0.2 to 1.5.

[0037] <17> <16> The method described herein, wherein the oral pharmaceutical preparation is a solid oral preparation.

[0038] Advantages of the present invention

[0039] According to the present invention, the unpleasant taste of ibuprofen can be reduced in oral pharmaceutical preparations containing ibuprofen. Detailed Implementation

[0040] <Oral pharmaceutical preparations>

[0041] The oral pharmaceutical formulation of the present invention is an oral pharmaceutical formulation in which the unpleasant taste of ibuprofen has been reduced; it comprises (A) ibuprofen or a salt thereof or a solvate thereof, and (B) magnesium oxide, wherein the weight ratio of component (A) to component (B) [(B) / (A)] is 0.2 to 1.5. Specifically, component (A) and component (B) are contained in a pharmaceutical formulation.

[0042] Component (A)

[0043] "Ibuprofen or its salts or solvates thereof" includes: ibuprofen; alkali metal salts of ibuprofen, such as ibuprofen sodium and ibuprofen potassium; and hydrates and alcohols thereof.

[0044] Ibuprofen or its salts or solvates thereof are preferably in the form of a powder. The average particle size of the powder is preferably 5 to 75 μm, more preferably 15 to 60 μm. The average particle size of the powder can be measured by laser diffraction.

[0045] Ibuprofen or its salts or solvates thereof can be produced by known methods or using commercial products.

[0046] From the viewpoint of reducing unpleasant taste and inhibiting discoloration during the formation step, the amount of ibuprofen or its salts or solvates thereof, relative to the total weight of the oral pharmaceutical preparation of the present invention, is preferably 1% to 85% by weight, more preferably 2.5% to 65% by weight, even more preferably 2.5% to 60% by weight, and even more preferably 4% to 50% by weight. If the oral pharmaceutical preparation of the present invention is a solid or semi-solid preparation, from the viewpoint of reducing unpleasant taste and inhibiting discoloration during the formation step, it is even more preferably 5% to 50% by weight, even more preferably 15% to 50% by weight, and particularly preferably 20% to 50% by weight. However, if the oral pharmaceutical preparation of the present invention is a liquid preparation, from the viewpoint of reducing unpleasant taste, it is particularly preferably 4% to 10% by weight.

[0047] Component (B)

[0048] Magnesium oxide can be light magnesium oxide or heavy magnesium oxide. There are no particular restrictions on the particle size, specific volume, etc. of magnesium oxide; the specific volume is preferably 1 to 12 mL / g, more preferably 2 to 10 mL / g.

[0049] Magnesium oxide can be produced by known methods or using commercial products. It should be noted that magnesium oxide-containing substances, such as synthetic hydrotalcite and sucralfate, can be used.

[0050] From the viewpoint of reducing unpleasant taste and inhibiting discoloration during the formation step, the magnesium oxide content, relative to the total weight of the oral pharmaceutical preparation of the present invention, is preferably 0.1% to 95% by weight, more preferably 0.25% to 85% by weight, even more preferably 0.5% to 75% by weight, and even more preferably 1% to 65% by weight. If the oral pharmaceutical preparation of the present invention is a solid or semi-solid preparation, from the viewpoint of reducing unpleasant taste and inhibiting discoloration during the formation step, it is even more preferably 1% to 55% by weight, and particularly preferably 1% to 40% by weight; if the oral pharmaceutical preparation of the present invention is a liquid preparation, from the perspective of reducing unpleasant taste, it is even more preferably 1% to 15% by weight, and particularly preferably 1% to 7.5% by weight.

[0051] The oral pharmaceutical formulation of the present invention comprises component (A) and component (B) in a weight ratio [(B) / (A)] of 0.2 to 1.5. If the weight ratio [(B) / (A)] is less than 0.2, the unpleasant taste of ibuprofen cannot be sufficiently reduced. If the weight ratio [(B) / (A)] in the solid oral formulation is greater than 1.5, the solid oral formulation is prone to turning black during production.

[0052] From the viewpoint of reducing unpleasant taste and inhibiting discoloration during the production step, the weight ratio [(B) / (A)] is preferably not less than 0.25, more preferably not less than 0.3, even more preferably not less than 0.35, and particularly preferably not less than 0.4; in addition, from the viewpoint of inhibiting the phenomenon of the formulation turning black during the production step, it is preferably not more than 1.45, more preferably not more than 1.25.

[0053] If the weight ratio [(B) / (A)] is 0.25 to 1.5, more preferably 0.3 to 1.5, even more preferably 0.35 to 1.5, even more preferably 0.4 to 1.5, even more preferably 0.4 to 1.45, and particularly preferably 0.4 to 1.25, the unpleasant taste of ibuprofen is further reduced.

[0054] Depending on the purpose of the formulation, the oral pharmaceutical preparations of the present invention may also contain drugs other than those described above. Examples of such drugs include antacids (other than magnesium oxide), anti-inflammatory agents (other than ibuprofen), hypnotics and sedatives, antitussives and expectorants, caffeine, antihistamines, antiallergics, anticholinergics, vitamins, muscle relaxants, crude drugs, etc. These can be used alone or in combination of two or more.

[0055] Examples of the antacids include sodium bicarbonate, precipitated calcium carbonate, calcium silicate, synthetic aluminum silicate, dicalcium phosphate, anhydrous dicalcium phosphate, aluminum hydroxide gel, dry aluminum hydroxide gel, aluminum hydroxide-sodium bicarbonate coprecipitate, aluminum hydroxide-magnesium carbonate mixed dry gel, aluminum hydroxide-magnesium carbonate-calcium carbonate coprecipitate, magnesium hydroxide-potassium aluminum sulfate coprecipitate, glycine, magnesium silicate, aluminum dihydroxyacetate, magnesium carbonate, etc. These can be used alone or in combination of two or more.

[0056] The amount of the antacid relative to the total weight of the oral pharmaceutical preparation of the present invention is preferably 0 to 5% by weight, more preferably 0 to 1% by weight, even more preferably 0 to 0.1% by weight, and particularly preferably 0 to 0.01% by weight.

[0057] Examples of such anti-inflammatory agents include glycyrrhizic acid and its salts, tranexamic acid, glycyrrhetinic acid, sodium azulene sulfonate, aspirin, salicylamide, etc. These can be used alone or in combination of two or more.

[0058] The amount of the anti-inflammatory agent is preferably 0 to 32% by weight, more preferably 0 to 25% by weight, relative to the total weight of the oral pharmaceutical preparation of the present invention.

[0059] Examples of such hypnotic and sedative drugs include allyl isopropyl acetylurea, bromoisovalerate, etc. These can be used alone or in combination of two or more.

[0060] The amount of the hypnotic sedative relative to the total weight of the oral pharmaceutical preparation of the present invention is preferably 0 to 42% by weight, more preferably 0 to 30% by weight.

[0061] Examples of the antitussives and expectorants mentioned include ambroxol hydrochloride, L-cysteine ​​ethyl ester hydrochloride, guaiacol sulfonate potassium, cresol sulfonate potassium, guaiacol glycerol ether, bromhexine hydrochloride, L-carbocisteine, codeine phosphate hydrate, codeine dihydrophosphate, tipepidine citrate, tipepidine hibenzate, dextromethorphan hydrobromide hydrate, dextromethorphan phenolphthalate, dimemorphan phosphate, noscapine, noscapine hydrochloride hydrate, d1-methylephedrine hydrochloride, and d1-methylephedrine saccharin salt. These can be used alone or in combination of two or more.

[0062] The amount of the antitussive and expectorant relative to the total weight of the oral pharmaceutical preparation of the present invention is preferably 0 to 56% by weight, more preferably 0 to 40% by weight.

[0063] Examples of caffeine include caffeine hydrate, anhydrous caffeine, sodium caffeine benzoate, etc. These can be used alone or in combination of two or more.

[0064] The amount of caffeine relative to the total weight of the oral pharmaceutical preparation of the present invention is preferably 0 to 28% by weight, more preferably 0 to 20% by weight.

[0065] Examples of the aforementioned antihistamines and antiallergic drugs include mequinatazine, azelastine hydrochloride, fexofenadine hydrochloride, epinastine hydrochloride, loratadine, cetirizine hydrochloride, olopatadine hydrochloride, alimazine tartrate, carbixamine maleate, chlormastine fumarate, d-chlorpheniramine maleate, dl-chlorpheniramine maleate, diphenhydramine hydrochloride, etc. These can be used alone or in combination of two or more.

[0066] Examples of such anticholinergic drugs include propiconamide iodide, scopolia extract, scopolia root, total alkaloids of belladonna, scopolamine hydrobromide, butylscopolamine bromide, methylbenactyzium bromide, timepidium bromide, and pirenzepine. These can be used alone or in combination of two or more.

[0067] Examples of the vitamins mentioned include vitamin B1, vitamin B1 derivatives, vitamin B2, vitamin B2 derivatives, vitamin C, vitamin C derivatives, hesperidin, hesperidin derivatives, and their salts. These can be used alone or in combination of two or more.

[0068] Examples of the crude drugs mentioned include *Pheretima aspergillum*, cinnamon, licorice, peony root, peony bark, citrus peel, ginger, *Zanthoxylum piperitum*, platycodon root, ephedra, apricot kernel, pinellia tuber, plantain, polygala root, bupleurum falcatum, and magnolia flower. These can be used alone or in combination of two or more.

[0069] Examples of muscle relaxants include mesocarbamol, chlorzoxazone, pridinol mesylate, chlorphenesin carbamate, etorizine hydrochloride, fluquinone, and tizanidine hydrochloride. These can be used alone or in combination of two or more.

[0070] The oral pharmaceutical formulations of the present invention may also contain pharmaceutical additives. Examples of such pharmaceutical additives include excipients, such as lactose, sucrose, glucose, mannitol, sorbitol, and xylitol; disintegrants, such as sodium carboxymethyl cellulose, crosspovidone, calcium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose (preferably 5% to 16% by weight), crystalline cellulose, and calcium carbonate; binders, such as gelatin, sodium alginate, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, and carboxymethyl cellulose; lubricants, such as magnesium stearate and talc; and fluidizing agents, such as light anhydrous silicate. These may be used alone or in combination of two or more. If necessary, solubilizers, buffers, preservatives, flavorings, colorings, tasters, etc., may also be used.

[0071] The total amount of the pharmaceutical additives is preferably 5% to 70% by weight, more preferably 10% to 50% by weight, relative to the total weight of the oral pharmaceutical preparation of the present invention.

[0072] It should be noted that if the oral pharmaceutical preparation of the present invention is a solid or semi-solid preparation, the water content of the oral solid or semi-solid preparation is preferably 0 to 7% by weight, more preferably 0 to 5% by weight.

[0073] However, if the oral pharmaceutical formulation of the present invention is a liquid formulation, the water content of the oral liquid formulation is preferably 40% to 99% by weight, more preferably 60% to 99% by weight, and particularly preferably 80% to 99% by weight.

[0074] The oral pharmaceutical formulations of the present invention can be in the form of solid dosage forms, semi-solid dosage forms, or liquid dosage forms. Solid dosage forms and semi-solid dosage forms are preferred. Even when the oral pharmaceutical formulations of the present invention are in the form of solid or semi-solid dosage forms, their unpleasant taste is difficult to detect.

[0075] Examples of specific liquid dosage forms include elixirs, syrups, suspensions, emulsions, lemonade, etc.

[0076] Examples of specific solid and semi-solid dosage forms include granules, fine granules, powders, tablets (uncoated tablets, OD tablets, chewable tablets, dispersible tablets, dissolving tablets, lozenges, sublingual tablets, buccal tablets, adhesive tablets, effervescent tablets, chewing gum, etc.), pills, capsules (soft capsules, hard capsules, etc.), dry syrups, gels, gummies, etc. These may be sugar-coated, film-coated, or coated with chocolate, etc., according to known methods.

[0077] Among specific solid and semi-solid dosage forms, granules, fine granules, powders, uncoated tablets, OD tablets, chewable tablets, chewing gum, jelly, and gummies are preferred; granules, fine granules, uncoated tablets, OD tablets, chewable tablets, jelly, and gummies are more preferred; granules, fine granules, uncoated tablets, OD tablets, chewable tablets, and gummies are even more preferred; and granules, uncoated tablets, OD tablets, chewable tablets, and gummies are particularly preferred. The average particle size is preferably 50 to 1000 μm, more preferably 50 to 500 μm. The average particle size can be measured by sieving.

[0078] Even in dosage forms that easily impart an unpleasant taste to ibuprofen, such as granules, fine granules, powders, uncoated tablets, OD tablets, chewable tablets, chewing gum, jelly, and soft candy, this invention can sufficiently reduce the unpleasant taste of ibuprofen. Furthermore, even in uncoated solid and semi-solid dosage forms, the unpleasant taste is difficult to detect. Moreover, even in tablets, it can suppress the darkening of the formulation during the production process, and thus can provide tablets with high commercial value.

[0079] The dosage of the oral pharmaceutical formulation of the present invention is preferably such that it allows oral administration of component (A) at a dose of 100 to 2400 mg / day, more preferably 120 to 1200 mg / day, and particularly preferably 390 to 1200 mg / day (calculated as free ibuprofen). Furthermore, it is preferably such that it allows oral administration of component (A) at a dose of 60 to 800 mg / application, more preferably 60 to 400 mg / application, even more preferably 70 to 400 mg / application, and particularly preferably 130 to 400 mg / application (calculated as free ibuprofen).

[0080] Additionally, a preferred amount is one that allows for oral administration of 30 to 1000 mg / day of magnesium oxide.

[0081] <Methods of production, methods for reducing unpleasant odors, and methods for inhibiting discoloration>

[0082] The oral pharmaceutical formulation of the present invention can be produced according to a dosage form by a known method; preferably, it is produced by a method comprising the following steps, wherein (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide are incorporated into the same composition such that the weight ratio of component (A) to component (B) in the oral pharmaceutical formulation [(B) / (A)] is 0.2 to 1.5 (hereinafter referred to as step 1). According to this method, an oral pharmaceutical formulation with a reduced unpleasant taste of ibuprofen can be readily produced. Furthermore, when a solid oral formulation is produced, the phenomenon of the formulation turning black during the production step can be suppressed.

[0083] Step 1

[0084] In step 1, the amounts of components (A) and (B) used should be adjusted so that the weight ratio of component (A) to component (B) [(B) / (A)] in the oral pharmaceutical formulation of the target invention is 0.2 to 1.5. The order in which components (A) and (B) are incorporated into the composition is irrelevant.

[0085] From the viewpoint of homogenization, reducing unpleasant taste, and inhibiting discoloration during the process, step 1 is preferably a step in which components (A) and (B), as well as any other necessary components (the aforementioned drug and pharmaceutical additives), are mixed such that the weight ratio of component (A) to component (B) [(B) / (A)] in the oral pharmaceutical formulation is 0.2 to 1.5. Specifically, it includes techniques for obtaining a mixture by mixing components (A) and (B), as well as any other necessary components, and techniques for mixing components (A) and (B), as well as any other necessary components, and, if necessary, kneading the resulting mixture with a solvent (e.g., water or hydrous alcohol) and granulating it by common methods to obtain granular material.

[0086] The aqueous alcohol preferably has an alcohol content of no more than 30% by weight. The alcohol is preferably a lower alcohol, such as ethanol or isopropanol. Examples of water used as a solvent include purified water, ion-exchanged water, etc.

[0087] The above mixing and kneading can be performed, for example, using a stirring mixer. Mixing is preferably performed at 20 to 1000 rpm for 0.5 to 10 minutes. Kneading is preferably performed for 0.5 to 10 minutes.

[0088] The granulation can be carried out by wet granulation or dry granulation, but wet granulation is preferred.

[0089] Examples of wet granulation methods include stirred granulation, fluidized bed granulation, and extrusion granulation; among these, extrusion granulation is preferred.

[0090] If the composition obtained in step 1 is a granular material, its average particle size is preferably 50 to 1000 μm, more preferably 100 to 500 μm. The average particle size can be measured by sieving.

[0091] It should be noted that the weight ratio of component (A) to component (B) in the composition obtained in step 1 [(B) / (A)] is preferably the same as the weight ratio of component (A) to component (B) in the oral pharmaceutical preparation of the target invention [(B) / (A)]. Furthermore, the composition obtained in step 1 is preferably a solid.

[0092] Step 2

[0093] The method of producing ibuprofen, as a method for reducing unpleasant odor and for inhibiting discoloration, preferably further includes a step of drying the composition obtained in step 1 (hereinafter referred to as step 2). Including such a step 2 can further reduce the unpleasant odor of ibuprofen.

[0094] Specific examples of drying techniques in step 2 include thermal drying, freeze drying, low-pressure drying, vacuum drying, ventilation drying, and spray drying. Thermal drying is particularly preferred from the viewpoint of reducing unpleasant odors. When using thermal drying, the heating temperature should be lower than the melting points of each component in the composition; preferably 50°C to 75°C, more preferably 52.5°C to 72.5°C, even more preferably 55°C to 70°C, even more preferably 57.5°C to 67.5°C, and particularly preferably 60°C to 67.5°C, from the viewpoint of reducing unpleasant odors.

[0095] From the viewpoint of reducing unpleasant taste, the duration of the drying treatment is preferably 0.5 to 120 hours, more preferably 0.5 to 96 hours, even more preferably 0.5 to 72 hours, even more preferably 0.5 to 48 hours, even more preferably 0.5 to 24 hours, and particularly preferably 0.5 to 18 hours.

[0096] Drying processes can be performed using equipment such as box dryers, fluidized bed granulators, low-pressure dryers, vacuum dryers, ventilated dryers, and spray dryers.

[0097] Furthermore, if steps 1 and 2 produce granular material, it can be ground, sieved, spheroidized, coated with sugar or polymer, etc., using a Marumerizer after steps 1 and / or 2. Additionally, if steps 1 and 2 produce granular material, the resulting granular material can be used without further modification into granules, fine particles, or powder. Tablets can also be obtained by compressing the granular material into tablets according to common methods, and capsules can be obtained by filling the granular material into capsules according to common methods.

[0098] Furthermore, a liquid formulation can be obtained by mixing the composition (specifically, the solid composition) obtained in steps 1 and 2 with water. This liquid formulation (liquid composition) can also be heat-treated. This heat treatment can further reduce the unpleasant taste of ibuprofen.

[0099] From the viewpoint of reducing unpleasant taste, the heating temperature of the liquid composition is preferably 50°C to 100°C, more preferably 52.5°C to 97.5°C, even more preferably 55°C to 95°C, even more preferably 57.5°C to 92.5°C, and particularly preferably 60°C to 90°C.

[0100] In addition, from the viewpoint of reducing unpleasant taste, the duration of heating of the liquid composition is preferably 0.5 to 120 hours, more preferably 0.5 to 96 hours, even more preferably 0.5 to 72 hours, even more preferably 0.5 to 48 hours, even more preferably 0.5 to 24 hours, and particularly preferably 0.5 to 18 hours.

[0101] The oral pharmaceutical formulation of the present invention obtained as described above reduces the unpleasant taste of ibuprofen. Furthermore, in the case of a solid oral formulation, it is obtained without turning black during the production step.

[0102] Therefore, the oral pharmaceutical formulation of the present invention can fully demonstrate the anti-inflammatory and analgesic effects of ibuprofen, and is very suitable for use as an antipyretic analgesic, cold medicine, sleep-improving medicine, and neuropsychiatric medicine.

[0103] Example

[0104] The present invention is described in detail below with reference to the embodiments, but the present invention is not limited to these embodiments. In the test examples, the ibuprofen used was ibuprofen 25 manufactured by BASF; the magnesium oxide used was heavy and light magnesium oxide manufactured by Kyowa Chemical Industry Co., Ltd.; and the magnesium chloride hexahydrate used was a premium reagent manufactured by Wako Pure Chemical Corporation.

[0105] Example 1

[0106] Ibuprofen was passed through a 30-mesh sieve completely, and the resulting ibuprofen was weighed into a glass bottle with magnesium oxide (Example 1) or magnesium chloride hexahydrate (Comparative Example 1) in the corresponding proportions shown in Table 1. The glass bottle was then sealed with a metal cap and mixed in a vortex mixer for 3 minutes.

[0107] Immediately after mixing, a sample equivalent to 200 mg of ibuprofen was placed in the mouth and held for 3 minutes without swallowing. Sensory evaluation of the unpleasant taste (irritation and bitterness) of the ibuprofen was performed over time. For the sample used in Reference Example 1 shown in Table 1 (ibuprofen that passed completely through a 30-mesh sieve), sensory evaluation was performed according to the above procedure using the following evaluation criteria. A relative evaluation of the results of Example 1 and Comparative Example 1 was conducted based on the evaluation results of the Reference Example 1 sample. The results are shown in Table 1.

[0108] Evaluation criteria

[0109] AA: No unpleasant odor was detected.

[0110] A: An unpleasant smell was detected, but not that unpleasant.

[0111] B: It has an unpleasant smell and is very offensive.

[0112] C: Unacceptable and unpleasant.

[0113] [Table 1]

[0114]

[0115] As shown in Table 1, the mixture of ibuprofen and magnesium chloride hexahydrate (Comparative Example 1) is similar to ibuprofen (Reference Example 1) in that both exhibit a distinctly unpleasant taste after being held in the mouth for 30 seconds.

[0116] On the other hand, the mixture in which the weight ratio of ibuprofen to magnesium oxide [(B) / (A)] is 1.25 (Example 1) did not exhibit such an unpleasant taste even after being held in the mouth for 45 seconds.

[0117] Example 2

[0118] Ibuprofen was passed completely through a 30-mesh sieve, and the resulting ibuprofen was weighed into glass vials with magnesium oxide (Examples 2 to 7 and Comparative Example 4) or magnesium chloride hexahydrate (Comparative Example 3) in the corresponding proportions shown in Table 2. The vials were then sealed with metal caps and mixed in a vortex mixer for 3 minutes. The sealed vials were then stored at 65°C for 15 hours and then cooled; thus obtaining samples of Examples 2 to 7 and Comparative Examples 3 to 4.

[0119] In addition, ibuprofen was completely passed through a 30-mesh sieve, and 200 mg of the obtained ibuprofen was introduced into a glass bottle. The glass bottle was then sealed with a metal cap, and the sealed bottle was stored at 65°C for 15 hours. After cooling, the sample of Comparative Example 2 was obtained.

[0120] Sensory evaluations (relative evaluations based on the evaluation results of the sample from Examples 2 to 7 and Comparative Examples 2 to 4) were conducted on the unpleasant taste (irritation and bitterness) of ibuprofen, according to the procedures and evaluation criteria used in Test Example 1. The results are shown in Table 2.

[0121] [Table 2]

[0122]

[0123] As shown in Table 2, the mixture of ibuprofen and magnesium chloride hexahydrate (Comparative Example 3) exhibited a distinctly unpleasant taste after being held in the mouth for 20 seconds. Furthermore, the mixture with a weight ratio [(B) / (A)] less than 0.2 (Comparative Example 4) exhibited a distinctly unpleasant taste after being held in the mouth for 30 seconds.

[0124] On the other hand, mixtures with a weight ratio [(B) / (A)] in the range of 0.2 to 1.25 (Examples 2 to 7) did not exhibit such an unpleasant taste even after being held in the mouth for 45 seconds.

[0125] Furthermore, it is clear from Tables 1 and 2 that when ibuprofen was dried (Comparative Example 2) or a mixture of ibuprofen and magnesium chloride hexahydrate was dried (Comparative Example 3), the unpleasant taste was not lower than that of the undried substance (Reference Example 1, Comparative Example 1).

[0126] On the other hand, when the mixture of ibuprofen and magnesium oxide was dried (Example 7), the unpleasant taste was even less than that of the undried substance (Example 1).

[0127] Example 3

[0128] Ibuprofen, magnesium oxide, and low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.) were weighed to a total of 50 g according to the corresponding proportions shown in Table 3 below. This was introduced into a mechanomill and mixed at 900 rpm for 3 minutes. Next, purified water as shown in Table 3 below was added, kneaded for 3 minutes, and then extruded and granulated. The resulting granules were dried using a box dryer (overnight at 65°C). The size was set to obtain the granules (16 to 60 mesh) of Examples 8 to 12 and Comparative Example 5.

[0129] Sensory evaluation of the unpleasant taste (irritation and bitterness) of ibuprofen was performed on granules equivalent to 200 mg of ibuprofen, based on the procedures and evaluation criteria used in Test Example 1 (a relative evaluation based on the evaluation results of the sample in Reference Example 1). The results are shown in Table 3.

[0130] [Table 3]

[0131]

[0132]

[0133] As shown in Table 3, particles with a weight ratio [(B) / (A)] less than 0.2 (Comparative Example 5) exhibited a distinctly unpleasant taste after being held in the mouth for 30 seconds.

[0134] On the other hand, particles with a weight ratio [(B) / (A)] of 0.2 to 1.25 (Examples 8 to 12) did not exhibit such an unpleasant taste even after being held in the mouth for 3 minutes.

[0135] Example 4

[0136] The same sensory evaluation as in Test Example 3 was performed, except that the composition of the particles was modified to the composition shown in Table 4, and the particles were evaluated only after being held in the mouth for 30 seconds and 1 minute. The results are shown in Table 4.

[0137] [Table 4]

[0138]

[0139]

[0140] Example 5

[0141] Weigh ibuprofen, magnesium oxide, and low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.) to a total of 50 g according to the corresponding proportions shown in Table 5 below. Introduce this mixture into a mechanomill and mix at 900 rpm for 3 minutes. Next, add an appropriate amount of purified water and knead the resulting system for 3 minutes, then extrude and granulate. Dry the resulting granules using a box dryer (overnight at 65°C). Set the size to obtain the granules of Example 14 (16 to 60 mesh sieve).

[0142] Sensory evaluation of the unpleasant taste (irritation and bitterness) of ibuprofen was performed on granules equivalent to 200 mg of ibuprofen, based on the procedures and evaluation criteria used in Test Example 1 (a relative evaluation based on the evaluation results of the sample in Reference Example 1). The results are shown in Table 5.

[0143] [Table 5]

[0144]

[0145] As shown in Table 5, the particles with a weight ratio [(B) / (A)] of 1.5 (Example 14) are similar to the particles of Examples 8 to 12 in that they do not exhibit such an unpleasant taste even after being held in the mouth for 3 minutes.

[0146] Example 6

[0147] Ibuprofen, magnesium oxide, and low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.) were weighed to a total of 50 g according to the corresponding proportions shown in Table 6 below. This was introduced into a Mechanomill and mixed at 900 rpm for 3 minutes. Next, an appropriate amount of purified water was added, and the resulting system was kneaded for 3 minutes, then extruded and granulated. The resulting granules were dried using a box dryer (overnight at 65°C). The size was set to obtain granules (16 to 60 mesh sieve). Next, a tableting powder was prepared by adding 1 part by weight of magnesium stearate to every 100 parts by weight of the obtained granules and mixing thoroughly. This powder was then compressed using a single-tablet press to obtain uncoated tablets (10 mm in diameter, 400 mg per tablet) as in Examples 15 to 16 and Reference Examples 2 to 3.

[0148] Immediately after production, the color of the surface and sides of the uncoated tablets was visually confirmed. Those that turned a different color (black) from the granular material were evaluated as "blackened," while those that did not show a color change relative to the granular material were evaluated as "not blackened." The results are shown in Table 6.

[0149] [Table 6]

[0150]

[0151] Example 7

[0152] Weigh out the particles of Example 11 prepared in Test Example 3 to obtain an amount equivalent to 400 mg of ibuprofen. These particles will be referred to as "particles of Example 17".

[0153] The granules of Example 17 were placed in the mouth and held for 3 minutes without swallowing, and the unpleasant taste (irritation and bitterness) of ibuprofen was sensorily evaluated over time. For the sample of Reference Example 4 (ibuprofen that passed completely through a 30-mesh sieve) shown in Table 7, a sensory evaluation of the equivalent of 400 mg of ibuprofen was performed according to the above procedure using the following evaluation criteria, and the evaluation of Example 17 was relative to the evaluation results of the Reference Example 4 sample. The results are shown in Table 7.

[0154] Evaluation criteria

[0155] AA: No unpleasant odor was detected.

[0156] A: An unpleasant smell was detected, but not that unpleasant.

[0157] B: It has an unpleasant smell and is very offensive.

[0158] C: Unacceptable and unpleasant.

[0159] [Table 7]

[0160]

[0161] As shown in Table 7, the particles with a weight ratio [(B) / (A)] of 0.5 did not have such an unpleasant taste even after holding the equivalent of 400 mg of ibuprofen in the mouth for 3 minutes.

[0162] Example 8

[0163] Preparation of liquid reagents-

[0164] Liquid reagents of Reference Example 5, Example 18 and Comparative Example 11 were prepared according to the following procedures.

[0165] Refer to Example 5 for liquid reagents

[0166] Ibuprofen was completely passed through a 30-mesh sieve, and the resulting ibuprofen was weighed into glass vials according to the proportions shown in Table 8. Next, the glass vials were sealed with metal caps, mixed in a vortex mixer for 3 minutes, and then purified water was added according to the proportions shown in Table 8, and the mixture was shaken to obtain a suspension, which was used as a liquid reagent in Reference Example 5.

[0167] Example 18 Liquid Reagent

[0168] Ibuprofen was passed completely through a 30-mesh sieve, and the resulting ibuprofen was then weighed with magnesium oxide into a glass bottle in the proportions shown in Table 8. The glass bottle was then sealed with a metal cap and mixed in a vortex mixer for 3 minutes. The total volume was then transferred to a plastic tray. The plastic tray was then stored at 65°C for 15 hours; after cooling, the resulting substance was crushed in a mortar and pestle, and purified water was added in the proportions shown in Table 8; the mixture was shaken to obtain a suspension, which was used as the liquid reagent in Example 18.

[0169] Comparative Example 11: Liquid Reagent

[0170] Ibuprofen was passed through a 30-mesh sieve, and the resulting ibuprofen was weighed with magnesium chloride hexahydrate into a glass bottle according to the proportions shown in Table 8. Next, the glass bottle was sealed with a metal cap, mixed in a vortex mixer for 3 minutes, and then purified water was added according to the proportions shown in Table 8 and shaken to obtain a suspension, which was used as the liquid reagent in Comparative Example 11.

[0171] -Evaluation of Liquid Reagents-

[0172] For the liquid reagents of Example 18 and Comparative Example 11, 10 g of the liquid reagent (equivalent to 400 mg ibuprofen) was introduced into the mouth and held for 3 minutes without swallowing. Sensory evaluation of the unpleasant taste (irritation and bitterness) of ibuprofen was performed over time. For 10 g of the liquid reagent of Reference Example 5, sensory evaluation was performed according to the above procedure using the following evaluation criteria. A relative evaluation of the evaluation results of Example 18 and Comparative Example 11 based on the evaluation results of the liquid reagent of Reference Example 5 was conducted. The results are shown in Table 8.

[0173] Evaluation criteria

[0174] AA: No unpleasant odor was detected.

[0175] A: An unpleasant smell was detected, but not that unpleasant.

[0176] B: It has an unpleasant smell and is very offensive.

[0177] C: Unacceptable and unpleasant.

[0178] [Table 8]

[0179]

[0180]

[0181] Example 9

[0182] Preparation of liquid reagents-

[0183] The liquid reagents of Reference Example 6, Example 19 and Example 20 were prepared according to the following procedures.

[0184] Refer to Example 6 for liquid reagents

[0185] The liquid reagent of Reference Example 5 was sealed and heated at 60°C for 2 hours to obtain the liquid reagent of Reference Example 6.

[0186] Example 19 Liquid Reagent

[0187] Ibuprofen was passed completely through a 30-mesh sieve, and the resulting ibuprofen was weighed with magnesium oxide into a glass bottle according to the proportions shown in Table 9. The glass bottle was then sealed with a metal cap and mixed in a vortex mixer for 3 minutes. Purified water was then added according to the proportions shown in Table 9, and the mixture was shaken to obtain a suspension. This suspension was then heated at 60°C for 2 hours while still sealed to obtain the liquid reagent of Example 19.

[0188] Example 20 Liquid Reagent

[0189] The liquid reagent of Example 18 was sealed and heated at 60°C for 2 hours to obtain the liquid reagent of Example 20.

[0190] -Evaluation of Liquid Reagents-

[0191] Sensory evaluations of the unpleasant taste (irritation and bitterness) of ibuprofen were performed using 10g of the liquid reagents from Reference Example 6 and Examples 19 to 20, respectively, according to the procedures and evaluation criteria used in Example 8 (relative evaluation based on the evaluation results of the liquid reagent from Reference Example 5). The results are shown in Table 9.

[0192] [Table 9]

[0193]

[0194] As shown in Tables 8 to 9, pharmaceutical formulations with a weight ratio [(B) / (A)] of 0.2 to 1.5 make it difficult to detect unpleasant tastes even when the dosage form is a liquid reagent.

[0195] Formulation Example 1: Powder

[0196] Weigh out 20g of ibuprofen (ibuprofen 25 manufactured by BASF), 5g of magnesium oxide (heavy-duty manufactured by Kyowa Chemical Industry Co., Ltd.), and 20g of low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.). Introduce these into a mechanomill (MM-20 manufactured by OKADA SEIKO CO., LTD.) and mix at 900 rpm for 3 minutes. Next, heat the resulting mixture in a box dryer set to 65°C for 12 hours. Then, sieve it through a No. 30 sieve with a mesh size of 500 μm to obtain a powder that passes through the No. 30 sieve. Add 25.75g of d-mannitol (Mannit P manufactured by Mitsubishi Corporation Life Sciences Limited), 0.25g of light anhydrous silica (Adsolider-101 manufactured by Fuji Silysia), 0.5g of aspartame (manufactured by Ajinomoto Co., Inc.), 0.5g of acesulfame potassium (manufactured by MC Food Specialties), and 0.5g of magnesium stearate (manufactured by TAIHEI CHEMICAL INDUSTRIAL CO., LTD. Botanical) to 22.5g of the obtained powder and mix; then perform aluminum heat-sealing filling so that each package contains 1000mg of powder.

[0197] Formulation Example 2: Granules

[0198] Weigh out 300g of ibuprofen (ibuprofen 25 manufactured by BASF), 300g of magnesium oxide (heavyweight manufactured by Kyowa Chemical Industry Co., Ltd.), and 450g of low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.). Introduce these into a vertical granulator (FM-VG-10 manufactured by Powrex) and mix for 3 minutes at a blade speed of 450 rpm and a shredder speed of 2000 rpm. Next, add 1800g of purified water and knead the resulting system for 3 minutes, then granulate using a 0.6mm sieve diameter (TDG-80A manufactured by Dalton). Introduce the resulting wet granules into a fluidized bed dryer (FLO-2 manufactured by Freund Corporation) and dry at an air-supply temperature of 85°C. Set the dimensions of these (QC-U10 manufactured by Powrex) to obtain the final granules. 361.5g of d-mannitol (Mannit P manufactured by Mitsubishi Corporation Life Sciences Limited), 5.5g of light anhydrous silica (Adsolider-101 manufactured by Fuji Silysia), 11g of aspartame (manufactured by Ajinomoto Co., Inc.), 11g of acesulfame potassium (manufactured by MC Food Specialties), and 11g of magnesium stearate (manufactured by TAIHEI CHEMICAL INDUSTRIAL CO., LTD. Botanical) were added to 700g of the obtained granules and mixed; then aluminum heat-sealing was performed to ensure that each package contained 1100mg of powder.

[0199] Formulation Example 3: Uncoated Tablets

[0200] Weigh out 500g of ibuprofen (ibuprofen 25 manufactured by BASF), 250g of magnesium oxide (heavyweight manufactured by Kyowa Chemical Industry Co., Ltd.), and 250g of low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.). Introduce these into a vertical granulator (FM-VG-10 manufactured by Powrex) and mix for 3 minutes at a blade speed of 450 rpm and a shredder speed of 2000 rpm. Next, add 1050g of purified water and knead the resulting system for 3 minutes, then granulate using a 0.6mm sieve diameter (TDG-80A manufactured by Dalton). Introduce the resulting wet granules into a fluidized bed dryer (FLO-2 manufactured by Freund Corporation) and dry at an air-supply temperature of 85°C. Set the dimensions of these (QC-U10 manufactured by Powrex) to obtain the final granules. 370g of crystalline cellulose (Ceolus PH-F20JP manufactured by Asahi Kasei), 6g of light anhydrous silica (Adsolider-101 manufactured by Fuji Silysia), 12g of talc (Lisblanc manufactured by Kihara Kasei) and 12g of magnesium stearate (manufactured by TAIHEI CHEMICAL INDUSTRIAL CO., LTD. Botanically) were added to 800g of the obtained granules and mixed; then tableting was performed to obtain uncoated tablets, each weighing 600mg and having a diameter of 12mm.

[0201] Formulation Example 4: Orally Disintegrating Tablets

[0202] Weigh out 600g of ibuprofen (ibuprofen 25 manufactured by BASF), 180g of magnesium oxide (heavyweight manufactured by Kyowa Chemical Industry Co., Ltd.), and 240g of low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.). Introduce these into a vertical granulator (FM-VG-10 manufactured by Powrex) and mix for 3 minutes at a blade speed of 450 rpm and a shredder speed of 2000 rpm. Next, add 1000g of purified water and knead the resulting system for 3 minutes, then granulate using a 0.6mm sieve diameter (TDG-80A manufactured by Dalton). Introduce the resulting wet granules into a fluidized bed dryer (FLO-2 manufactured by Freund Corporation) and dry at an air-supply temperature of 85°C. Set the dimensions of these (QC-U10 manufactured by Powrex) to obtain the final granules. 270g of crystalline cellulose (Ceolus PH-F20JP manufactured by Asahi Kasei), 100g of cropovidone (CL-F manufactured by BASF), 6g of light anhydrous silica (Adsolider-101 manufactured by Fuji Silysia), 11g of aspartame (manufactured by Ajinomoto Co., Inc.), 11g of acesulfame potassium (manufactured by MC Food Specialties), 11g of talc (Lisblanc manufactured by Kihara Kasei), and 11g of magnesium stearate (manufactured by TAIHEI CHEMICAL INDUSTRIAL CO., LTD. Botany) were added to 680g of the obtained granules and mixed; then tableting was performed to obtain orally disintegrating tablets, each weighing 550mg and having a diameter of 12mm.

[0203] Formulation Example 5: Chewable Tablets

[0204] Weigh out 500g of ibuprofen (ibuprofen 25 manufactured by BASF), 250g of magnesium oxide (heavyweight manufactured by Kyowa Chemical Industry Co., Ltd.), and 250g of low-substituted hydroxypropyl cellulose (L-HPC (LH31) manufactured by Shin-Etsu Chemical Co., Ltd.). Introduce these into a vertical granulator (FM-VG-10 manufactured by Powrex) and mix for 3 minutes at a blade speed of 450 rpm and a shredder speed of 2000 rpm. Next, add 1100g of purified water and knead the resulting system for 3 minutes, then granulate using a 0.6mm sieve diameter (TDG-80A manufactured by Dalton). Introduce the resulting wet granules into a fluidized bed dryer (FLO-2 manufactured by Freund Corporation) and dry at an air-supplied temperature of 85°C. Set the dimensions of these (QC-U10 manufactured by Powrex) to obtain the final granules. 200g of crystalline cellulose (Ceolus PH-F20JP manufactured by Asahi Kasei), 246g of d-mannitol (Granutol R manufactured by Freund Corporation), 6g of light anhydrous silica (Adsolider-101 manufactured by Fuji Silysia), 12g of aspartame (manufactured by Ajinomoto Co., Inc.), 12g of acesulfame potassium (manufactured by MCFood Specialties), 12g of talc (Lisblanc manufactured by Kihara Kasei), and 12g of magnesium stearate (manufactured by TAIHEI CHEMICAL INDUSTRIAL CO., LTD. Botanically) were added to 800g of the obtained granules and mixed; then tableting was performed to obtain chewable tablets, each weighing 650mg and having a diameter of 12mm.

Claims

1. A method for reducing the unpleasant taste of ibuprofen in an oral pharmaceutical preparation containing ibuprofen or a salt thereof or a solvate thereof, comprising the steps of incorporating (A) ibuprofen or a salt thereof or a solvate thereof and (B) magnesium oxide into the same composition so that the weight ratio of component (A) to component (B) [(B) / (A)] in the oral pharmaceutical preparation is 0.25 to 1.5, and drying the composition obtained in the above steps at 60° C. to 75° C., The dosage form of oral pharmaceutical preparations is granules, powders, uncoated tablets, orally disintegrating tablets, chewable tablets, chewing gum, jelly or soft candy.

2. The method according to claim 1, wherein: The granules are fine granules.